On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section … [Read more…]
CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that it has been named to 3BL Media’s 100 Best Corporate Citizens ranking for the second year in a row for environmental, social and governance (ESG) transparency and performance. 3BL … [Read more…]
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]
LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the Society for Investigative Dermatology’s (SID) annual meeting, held from May 18-21, 2022 in Portland, OR. Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research … [Read more…]
New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.–(BUSINESS WIRE)–Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression … [Read more…]
Promising preclinical data for NGN-401 presented at 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrate significant survival benefit and reduced disease burden in Rett syndrome mouse model Results show Neurogene’s EXACT gene therapy regulates MECP2 gene expression to target levels, avoiding overexpression related toxicity EXACT platform holds potential to … [Read more…]
MENLO PARK, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. … [Read more…]
Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets Results show consistent rescue of CFTR function across multiple cystic fibrosis patient genotypes, including genotypes that do not respond to approved CFTR modulator treatments MENLO PARK, Calif. … [Read more…]
LCAP shareholders have approved the previously announced business combination at the Special Meeting held on May 18, 2022 Transaction Expected to Close May 20, 2022 CORAL GABLES, Fla.–(BUSINESS WIRE)–Lionheart Acquisition Corporation II (Nasdaq: LCAPU, LCAP, LCAPW, “Lionheart” or “LCAP”), a publicly traded special purpose acquisition company, today announced that shareholders of record as of April … [Read more…]
